Tag: Levosimendan

Tenax Therapeutics Completes Enrollment in Phase 2 Pulmonary Hypertension Trial

HELP study exceeds target enrollment with 37 patients 84% initial open-label lead-in response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced, on average, by 7.5 mmHg during exercise following the initial levosimendan infusion No serious drug-related adverse events have been reported to date Top-line data expected […]